Sonal Singh to Risk Assessment
This is a "connection" page, showing publications Sonal Singh has written about Risk Assessment.
Connection Strength
0.953
-
Fukunaga MI, Halligan K, Kodela J, Toomey S, Furtado VF, Luckmann R, Han PKJ, Mazor KM, Singh S. Tools to Promote Shared Decision-Making in Lung Cancer Screening Using Low-Dose CT Scanning: A Systematic Review. Chest. 2020 12; 158(6):2646-2657.
Score: 0.108
-
Tang W, Chang HY, Zhou M, Singh S. Risk of Gastrointestinal Bleeding Among Dabigatran Users - A Self Controlled Case Series Analysis. Sci Rep. 2017 01 20; 7:40120.
Score: 0.085
-
Puhan MA, Yu T, Stegeman I, Varadhan R, Singh S, Boyd CM. Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer. BMC Med. 2015 Oct 01; 13:250.
Score: 0.078
-
Singh S, Loke YK, Enright P, Furberg CD. Republished: pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Postgrad Med J. 2014 Apr; 90(1062):205-7.
Score: 0.070
-
Puhan MA, Singh S, Weiss CO, Varadhan R, Boyd CM. A framework for organizing and selecting quantitative approaches for benefit-harm assessment. BMC Med Res Methodol. 2012 Nov 19; 12:173.
Score: 0.064
-
Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012 Aug 20; 13:138.
Score: 0.062
-
Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013 Jan; 68(1):114-6.
Score: 0.062
-
Singh S, Furberg CD. Inhaled anticholinergics for chronic obstructive pulmonary disease: comment on "Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease". Arch Intern Med. 2011 May 23; 171(10):920-2.
Score: 0.057
-
Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011 Aug; 66(8):699-708.
Score: 0.057
-
Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009 Feb 09; 169(3):219-29.
Score: 0.049
-
Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 2009; 32(3):219-28.
Score: 0.049
-
Navaneethan SD, Aloudat S, Singh S. A systematic review of patient and health system characteristics associated with late referral in chronic kidney disease. BMC Nephrol. 2008 Feb 25; 9:3.
Score: 0.046
-
Singh S, Trivedi AN. Spontaneous reports as evidence of adverse drug reactions. South Med J. 2008 Jan; 101(1):16.
Score: 0.045
-
Singh S, Shrivastava R, Das V. Formulary conversion programs: the need for patient-specific risk assessment. MedGenMed. 2004 Sep 14; 6(3):28.
Score: 0.036
-
Fain KM, Yu T, Li T, Boyd CM, Singh S, Puhan MA. Evidence selection for a prescription drug's benefit-harm assessment: challenges and recommendations. J Clin Epidemiol. 2016 06; 74:151-7.
Score: 0.020
-
Chang HY, Hsieh CF, Singh S, Tang W, Chiang YT, Huang WF. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan. Pharmacoepidemiol Drug Saf. 2015 Jun; 24(6):567-75.
Score: 0.019
-
Cavallazzi R, El-Kersh K, Abu-Atherah E, Singh S, Loke YK, Wiemken T, Ramirez J. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review. Respir Med. 2014 Nov; 108(11):1569-80.
Score: 0.018
-
Yu T, Fain K, Boyd CM, Singh S, Weiss CO, Li T, Varadhan R, Puhan MA. Benefits and harms of roflumilast in moderate to severe COPD. Thorax. 2014 Jul; 69(7):616-22.
Score: 0.017
-
Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost. 2008 Jan; 99(1):38-43.
Score: 0.011